Cargando…

Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer

BACKGROUND: Docetaxel is the only FDA-approved first-line treatment for castration-resistant prostate cancer (CRPC) patients. Docetaxel treatment inevitably leads to tumour recurrence after an initial therapeutic response with generation of multinucleated polyploid (MP) cells. Here we investigated r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mittal, Karuna, Donthamsetty, Shashi, Kaur, Ramneet, Yang, Chunhua, Gupta, Meenakshi V, Reid, Michelle D, Choi, Da Hoon, Rida, Padmashree C G, Aneja, Ritu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418452/ https://www.ncbi.nlm.nih.gov/pubmed/28334734 http://dx.doi.org/10.1038/bjc.2017.78

Ejemplares similares

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
por: Lin, H-M, et al.
Publicado: (2014)

A centrosome clustering protein, KIFC1, predicts aggressive disease course in serous ovarian adenocarcinomas
por: Mittal, Karuna, et al.
Publicado: (2016)

Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
por: Lee, J-L, et al.
Publicado: (2014)

Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers
por: Pannu, Vaishali, et al.
Publicado: (2015)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response
por: Domanitskaya, N, et al.
Publicado: (2014)

Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy
por: Tan, Q, et al.
Publicado: (2015)

CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance
por: Martinez, V G, et al.
Publicado: (2008)

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
por: Michlmayr, A, et al.
Publicado: (2010)

Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms
por: Legrier, M-E, et al.
Publicado: (2007)

Panoptic View of Prognostic Models for Personalized Breast Cancer Management
por: Saini, Geetanjali, et al.
Publicado: (2019)

Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer
por: Wei, J, et al.
Publicado: (2014)

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
por: Hendrikx, J J M A, et al.
Publicado: (2014)

Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer
por: Qu, Sifeng, et al.
Publicado: (2018)

NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines
por: Yang, Y, et al.
Publicado: (2006)

Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1
por: Mimeault, M, et al.
Publicado: (2013)

Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel
por: Uzoh, C C, et al.
Publicado: (2011)

KIFCI, a novel putative prognostic biomarker for ovarian adenocarcinomas: delineating protein interaction networks and signaling circuitries
por: Pawar, Shrikant, et al.
Publicado: (2014)

Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells
por: Mittal, Karuna, et al.
Publicado: (2017)

Loss of SLCO1B3 drives taxane resistance in prostate cancer
por: de Morrée, Ellen S, et al.
Publicado: (2016)

Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis
por: Roos, Alison, et al.
Publicado: (2015)

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
por: Glaysher, S, et al.
Publicado: (2010)

Repression of the autophagic response sensitises lung cancer cells to radiation and chemotherapy
por: Karagounis, Ilias V, et al.
Publicado: (2016)

Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1α-dependent Induction of Polo-Like Kinase 4
por: Mittal, Karuna, et al.
Publicado: (2022)

In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
por: Ashley, D M, et al.
Publicado: (2008)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy
por: de Graaff, Marieke A, et al.
Publicado: (2016)

A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes
por: Dutta, B, et al.
Publicado: (2012)

Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer
por: Li, Meng, et al.
Publicado: (2017)

Tyrphostins reduce chemotherapy-induced intestinal injury in mice: assessment by a biochemical assay
por: Zlotnik, Y, et al.
Publicado: (2005)

Photochemical internalisation of chemotherapy potentiates killing of multidrug-resistant breast and bladder cancer cells
por: Adigbli, D K, et al.
Publicado: (2007)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer
por: Wang, X, et al.
Publicado: (2014)

Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer
por: Ramcharan, K S, et al.
Publicado: (2014)

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
por: Parra, Karla, et al.
Publicado: (2017)

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
por: Fürstenberger, G, et al.
Publicado: (2006)

Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa
por: de Bruijn, M T, et al.
Publicado: (2010)

Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies
por: McCoy, M J, et al.
Publicado: (2012)

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
por: Liu, W M, et al.
Publicado: (2010)

Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
por: Azimi, A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fc3qa9nptb197k74eooi1hcgq7